The drug was shown to ameliorate the symptoms in PAH patients and prevent the development of PAH in BMPR2 deficient mice (Spiekerkoetter et al., 2015; Sommer et al., 2019). Here, BMPR2 is linked to pulmonary arterial hypertension.